Evaluation for psoriatic arthritis in dermatology clinics

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 2, 2009, Pages

  O'Reilly, Darren D ^a   Rahman, Proton ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ARTHRALGIA; ARTHRITIS; ARTICLE; DACTYLIS; HUMAN; JOINT EFFUSION; JOINT STIFFNESS; JOINT SWELLING; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE; NAIL DYSTROPHY; OSSIFICATION; PHYSICAL EXAMINATION; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY;

ARTHRITIS, PSORIATIC; CANADA; DERMATOLOGY; HOSPITALS, SPECIAL; HUMANS; INCIDENCE; PREVALENCE; PSORIASIS;

EID: 70449412144     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00025     Document Type: Article

References (16)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
2. Taylor W, Gladman D, Helliwell P, et al; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
3. Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007;57:1560-3.
4. Wright V, Moll JMH. Psoriatic arthritis. In: Wright V, Moll JMH, editors. Seronegative polyarthritis. Amsterdam: North Holland Publishing Co; 1976. p. 169-223.
5. Gladman DD. Psoriatic arthritis. In: Gordon K, Ruderman E, editors. Psoriasis and psoriatic arthritis. Berlin: Springer-Verlag; 2005. p. 57-65.
6. Khan M, Schentag C, Gladman D. Clinical and radiological changes during psoriatic arthritis disease progression: working toward classification criteria. J Rheumatol 2003;30:1022-6.
7. Mease PJ, Ory P, Sharp JT, et al. Adalimumab sustains inhibition of joint damage for more than 2 years in patients with PsA [abstract]. Ann Rheum Dis 2008;67 Suppl II:99.
8. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
9. Brockbank JE, Schentag C, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees [abstract]. Arthritis Rheum 2001;44 Suppl 9:S94.
10. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2:ii14-7.
11. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999;26:1752-6.
12. Chandran V, Cook R, Helliwell P, et al. International Multi-centre Psoriasis and Psoriatic Arthritis Reliability Trial (GRAPPA-IMPART): assessment of skin, joints, nails and dactylitis. Arthritis Rheum 2007;56 Suppl 9:S798.
13. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009;68:497-501.
14. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68;1387-94
15. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
16. Gladman DD. Adalimumab, etanercept, and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol 2008;4:510-1.